Literature DB >> 7688677

Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline.

E Weber1, H P Lehmann, A G Beck-Sickinger, E J Wawrzynczak, R Waibel, G Folkers, R A Stahel.   

Abstract

We recently described the identity of the small cell lung cancer (SCLC) cluster-w4 antigen and the human B cell differentiation marker CD24, a glycosylphosphatidylinositol (GPI)-anchored, highly glycosylated surface molecule of only 31-35 amino acids [15]. The specificities of three anti-cluster-w4 and of eleven anti-CD24 MoAbs have been investigated with respect to their binding capacity to the protein core of cluster-w4/CD24 antigen. Four overlapping peptides spanning this protein core were synthesized. MoAbs shown to bind to two overlapping peptides by antibody binding inhibition using the cluster-w4/CD24-positive SCLC cell line SW2 and by direct peptide binding detected in an ELISA were investigated in more detail. To determine the exact epitopes recognized by these MoAbs, an epitope mapping assay using peptides synthesized onto polyethylene pins was established. The three anti-cluster-w4 MoAbs SWA11, SWA21 and SWA22 and the anti-CD24 MoAbs OKB2 and ALB9 recognized the same short leucine-alanine-proline (LAP) sequence in an area without potential glycosylation sites close to the GPI anchor of the protein core of the cluster-w4/CD24 antigen.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688677      PMCID: PMC1554848          DOI: 10.1111/j.1365-2249.1993.tb07980.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Continuous and discontinuous protein antigenic determinants.

Authors:  D J Barlow; M S Edwards; J M Thornton
Journal:  Nature       Date:  1986 Aug 21-27       Impact factor: 49.962

Review 2.  Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures.

Authors:  M A Ferguson; A F Williams
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

3.  Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells.

Authors:  O W Press; P J Martin; P E Thorpe; E S Vitetta
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

4.  Strategies for epitope analysis using peptide synthesis.

Authors:  H M Geysen; S J Rodda; T J Mason; G Tribbick; P G Schoofs
Journal:  J Immunol Methods       Date:  1987-09-24       Impact factor: 2.303

5.  Monoclonal antibody BA-1 recognizes a novel human leukocyte cell surface sialoglycoprotein complex.

Authors:  S J Pirruccello; T W LeBien
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

6.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.

Authors:  H M Geysen; R H Meloen; S J Barteling
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

7.  Monoclonal antibodies defining markers with apparent selectivity for particular haemopoietic cell types may also detect antigens on cells of neural crest origin.

Authors:  J T Kemshead; J Fritschy; U Asser; R Sutherland; M F Greaves
Journal:  Hybridoma       Date:  1982

8.  Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules.

Authors:  G F Fischer; O Majdic; S Gadd; W Knapp
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

9.  Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, BL3) on human B lymphocytes.

Authors:  C Y Wang; W Azzo; A Al-Katib; N Chiorazzi; D M Knowles
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

10.  Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11.

Authors:  A Smith; R Waibel; G Westera; A Martin; A T Zimmerman; R A Stahel
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

View more
  6 in total

1.  Identification of a novel dendritic cell surface antigen defined by carbohydrate specific CD24 antibody cross-reactivity.

Authors:  L A Williams; A D McLellan; K L Summers; R V Sorg; D B Fearnley; D N Hart
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

2.  Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface.

Authors:  Marei Sammar; Monika Siwetz; Hamutal Meiri; Viktor Fleming; Peter Altevogt; Berthold Huppertz
Journal:  Histochem Cell Biol       Date:  2016-12-23       Impact factor: 4.304

3.  CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization.

Authors:  Jonathan B Overdevest; Shibu Thomas; Glen Kristiansen; Donna E Hansel; Steven C Smith; Dan Theodorescu
Journal:  Cancer Res       Date:  2011-04-11       Impact factor: 12.701

4.  Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells.

Authors:  Sara Haddock; Tyler J Alban; Şevin Turcan; Hana Husic; Eric Rosiek; Xiaoxiao Ma; Yuxiang Wang; Tejus Bale; Alexis Desrichard; Vladimir Makarov; Sebastien Monette; Wei Wu; Rui Gardner; Katia Manova; Adrienne Boire; Timothy A Chan
Journal:  Neoplasia       Date:  2022-04-07       Impact factor: 6.218

5.  CD24 regulated gene expression and distribution of tight junction proteins is associated with altered barrier function in oral epithelial monolayers.

Authors:  Ping Ye; Mangala A Nadkarni; Mary Simonian; Neil Hunter
Journal:  BMC Cell Biol       Date:  2009-01-13       Impact factor: 4.241

6.  Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients.

Authors:  Michael Majores; Anne Schindler; Angela Fuchs; Johannes Stein; Lukas Heukamp; Peter Altevogt; Glen Kristiansen
Journal:  BMC Clin Pathol       Date:  2015-11-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.